Boehringer Ingelheim has turned down its chance to license Nxera Pharma’s phase 2-ready schizophrenia drug candidate, depriving the Japanese drugmaker of a 60 million euro ($70 million) option payment ...

Numab to receive milestone payment. BoehringerIngelheimhasadvanceditsnovelmulti-specificantibodyforretinal diseasesresultingfromacollaborationwithNumabintopreclinicaldevelopment.

Nxera Pharma, which recently announced a number of job cuts in Cambridge, is putting on a brave face after suffering another ...

Galux has signed a research agreement with Boehringer Ingelheim to jointly explore the application of AI in precision protein ...

Tokyo, Japan and Cambridge, UK, 19 December 2025 – Nxera Pharma Co. Ltd (“Nxera” or “the Company; TSE 4565) today announces that Boehringer ...

Sosei Group ( ($JP:4565) ) has provided an announcement. Nxera Pharma will regain full rights to its GPR52 agonist program for schizophrenia, ...

Galux signed a research agreement with Boehringer Ingelheim to advance AI-driven precision protein design for next-generation ...

Even as obesity and diabetes heavyweights Eli Lilly and Novo Nordisk command headlines with their global manufacturing expansions, Boehringer Ingelheim is getting in on the action. Thursday, ...

AbbVie, Bristol Myers Squibb, Gilead, Merck and other drugmakers are expected on Friday afternoon ​to announce agreements ...

Boehringer Ingelheim unveiled its evolved company brand this week, featuring the corporate claim: “Life forward.” The German pharma giant said the claim builds upon the company’s purpose of ...

Boehringer Ingelheim joins forces with Belgian biotech company GST which develops and produces state-of-the art stem cell products for horses and pets The acquisition follows two years of successful ...

INGELHEIM, Germany & BEIJING, China--(BUSINESS WIRE)--Boehringer Ingelheim and Peking University (PKU) today announced an ambitious strategic partnership with the aim of jointly advancing early ...